Scientists identify KRAS rearrangements in metastatic prostate cancer

Apr 03, 2011

Scientists have uncovered a genetic characteristic of metastatic prostate cancer that defines a rare sub-type of this disease. These findings are published in Cancer Discovery, the newest journal of the American Association for Cancer Research, which will debut at the AACR 102nd Annual Meeting 2011, held April 2-6.

Arul M. Chinnaiyan, M.D., Ph.D., an investigator of the Howard Hughes Medical Institute and director of the Michigan Center for Translational Pathology, and colleagues identified an oncogenic gene fusion of KRAS, one of the most studied and well-known oncogenes in a metastatic prostate cancer cell line.

Like most metastatic disease, metastatic prostate cancer has a grim prognosis. As scientists learn more about the of this disease, they may be able to work backward and accurately predict which early-stage prostate cancers will be more aggressive and thus require additional therapy and management.

"Right now, we can identify the presence of prostate cancer but not accurately predict which of these cancers will have a poor prognosis," said Chinnaiyan. "Although prostate cancer is a leading cause of cancer-related death, we need better prognostic information to separate the slow growing tumors from the more aggressive ones."

Chinnaiyan compared the identification of the KRAS gene in metastatic to the work that has been previously done in breast cancer, where scientists now recognize that breast cancer comes in multiple subtypes and requires different treatment strategies.

"The more we know about the disease biologically, the better we'll be able to treat it," said Chinnaiyan.

Currently, there are no treatments that block the KRAS , but several are under development that target components of the KRAS signaling pathway.

Explore further: Possibilities for personalised vaccines revealed at ESMO Symposium

add to favorites email to friend print save as pdf

Related Stories

Metabolite Linked to Aggressive Prostate Cancer

Feb 11, 2009

Researchers from the University of Michigan Comprehensive Cancer Center have identified a panel of small molecules, or metabolites, that appear to indicate aggressive prostate cancer.

Scientists target aggressive prostate cancer

Mar 02, 2011

Researchers at the University of Michigan Comprehensive Cancer Center have identified a potential target to treat an aggressive type of prostate cancer. The target, a gene called SPINK1, could be to prostate ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

19 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

23 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.